However, various PARPi may have different cytotoxic potential and toxic side effects on tumor cells owing to their different ability to induce PARP reverse conformation, which makes the OS outcome of patients with BC show considerable variability: whereas EMBRACA and BROCADE3 reported statistically significant OS improvements, OlympiAD revealed only a nonsignificant trend toward OS benefit.
← all excerpts
PARP inhibitors and breast cancer: from therapeutic breakthrough to resistance challenge.
1
—
—